{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-129738","form_type":"8-K","ticker":"KPRX","cik":"0001372514","company_name":"KIORA PHARMACEUTICALS INC","filed_at":"2021-10-26T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.277010+00:00","generated_at":"2026-06-28T17:55:14.508371+00:00","sec_items":["1.01","2.01","5.02","3.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"EyeGate closes Bayon acquisition, issues 33,798 shares; appoints Eric Daniels as CDO","bullets":["Acquired Bayon Therapeutics for 33,798 common shares; up to $7.1M in milestone payments possible.","Eric Daniels appointed CDO with base salary AUD$492,000 and option for 50,000 shares.","CEO Brian Strem and new CDO Eric Daniels each owned ~28% of Bayon before acquisition.","Milestone payments tied to clinical trial data and FDA approval of Bayon product candidates."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-129738","json":"https://secwatch.observer/filing/0001104659-21-129738.json","markdown":"https://secwatch.observer/filing/0001104659-21-129738.md","text":"https://secwatch.observer/filing/0001104659-21-129738.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372514/000110465921129738/0001104659-21-129738-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372514/000110465921129738/tm2130996d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T17:55:14.508371+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3a93ee9d27","claim":"Eric J. Daniels was appointed as Chief Development Officer at KIORA PHARMACEUTICALS INC.","evidence_excerpt":"the Board of Directors (the “Board”) of the Company appointed Eric J. Daniels, MD, MBA as Chief Development Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372514/000110465921129738/0001104659-21-129738-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Development Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}